[ad_1]
THURSDAY, Aug. 3, 2023 (HealthDay Information) — A Louisiana lady is suing the makers of two kind 2 diabetes medicine used off-label for weight problems, saying they didn’t adequately warn concerning the danger of extreme abdomen issues.
The lawsuit seeks “very vital” however unspecified compensation from the makers of each Ozempic and Mounjaro, mentioned lawyer Paul Pennock of the Orlando, Fla.-based agency Morgan & Morgan.
Pennock filed the lawsuit Wednesday on behalf of Jaclyn Bjorklund, 44, NBC Information reported.
The lawsuit in opposition to Novo Nordisk and Eli Lilly claims Bjorklund was “severely injured” after taking the 2 diabetes medicine, that are a part of a brand new class of treatment known as GLP-1 agonists.
Pennock mentioned she is struggling “persistent” vomiting and extreme gastroparesis, often known as abdomen paralysis.
Gastroparesis slows or stops meals from shifting out of the abdomen and into the small intestines. It may be attributable to underlying medical points, together with diabetes, in response to the American Faculty of Gastroenterology. Infections and a few treatment may trigger it.
The GLP-1 agonists gradual meals’s motion and have been discovered to trigger some GI points in medical trials. These are listed as negative effects on the drug labels.
Each Ozempic and Mounjaro have the phrase “delays gastric emptying” on their prescribing info, although they don’t particularly use the phrase “gastroparesis,” NBC Information reported.
A U.S. Meals and Drug Administration spokeswoman mentioned it was unclear whether or not the GLP-1 medicines contribute to gastroparesis.
“If newly recognized security indicators are recognized, the FDA will decide what actions are applicable after an intensive evaluate of the physique of proof,” spokeswoman Chanapa Tantibanchachai mentioned in a press release.
Eli Lilly didn’t reply to an NBC Information request for remark, and a Novo Nordisk spokeswoman mentioned the corporate was unaware of the lawsuit.
“Affected person security is of utmost significance to Novo Nordisk,” mentioned spokeswoman Natalia Salomao. “We advocate sufferers take these medicines for his or her accepted indications and beneath the supervision of a well being care skilled.”
Extra info
There’s extra about GLP-1 agonists and weight reduction on the Mayo Clinic.
SOURCE: NBC Information
Copyright © 2023 HealthDay. All rights reserved.
[ad_2]
Source link
